Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
$9.79
$0.06(0.58%)
At close: 4:00 PM EST
$9.79
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$5.60 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)2.98M
Market Cap
$770.56M
Enterprise Value$951.35M
Total Cash (Recent Filing)$55.72M
Total Debt (Recent Filing)$148.92M
Price to Earnings (P/E)4.8
Beta1.53
Next Earnings
Mar 31, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding78,789,050
10 Day Avg. Volume2,483,506
30 Day Avg. Volume2,978,814
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)5.63
Price to Sales (P/S)10.97
P/FCF Ratio-9.40
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue4.44
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda8.47
Forecast
1Y Price Target
$18.40Price Target Upside87.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)2.59
Revenue Forecast (FY)$301.30M
Bulls Say, Bears Say
Bulls Say
Acquisition And DiversificationThe acquisition of Melinta now closed, CRMD has a much more diversified business going into 2026.
Financial PerformanceCorMedix reported better than forecast metrics across the board, with 3Q25 net revenue of $104.3M driven by higher utilization of DefenCath among outpatient dialysis customers.
Sales GuidanceAnalyst raised its full-year 2025 pro forma net revenue guidance to $390–$410M, compared with prior guidance of at least $375M.
Bears Say
Price CompressionSignificant price compression is expected to drive sales contractions in 2026 and 2027.
Price Target AdjustmentUncertainty regarding DefenCath's future price levels led to an adjustment in the price target from $20 to $16.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $5.60 and its highest was $17.43 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $770.56M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Mar 31, 2026 which is in 117 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Nov 12, 2025. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.634 by $0.626.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.84.
How many shares outstanding does Cormedix have?
Cormedix has 78,789,050 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $1.26 in its last earnings report, beating expectations of $0.634. Following the earnings report the stock price went up 2.055%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.40 (87.95% Upside)
$18.40 (87.95% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.70%
12-Months-Change
Fundamentals
Return on Equity
75.08%
Trailing 12-Months
Asset Growth
867.78%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a transformative quarter for CorMedix, marked by record financial performance, strategic acquisitions, and promising future growth catalysts. Despite increased operating expenses and uncertainties surrounding DefenCath's post-TDAPA pricing, the company's strong revenue growth and strategic investments indicate a positive outlook.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$18.40
▲(87.95% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.18% Insiders
9.07% Mutual Funds
4.90% Other Institutional Investors
72.64% Public Companies and Individual Investors